


Preferred CRO partner

14 June 2010 | News

image not found or type unknown



15
Synthetis Personal




Head:

Goutam Das (COO)

Business:

Custom research and
manufacturing of
biopharmaceuticals



Startup Year:
1994

Address:
Biocon Park, Plot No.: 2-3,
Bommasandra IV phase, Jigini
link road, Bangalore-560099,
Karnataka

Tel:
+91-80-28082808

Fax:
+91-80-28083150

Website:
www.syngeneintl.com

Syngene International (Syngene), a subsidiary of the biopharma major Biocon, is an internationally reputed custom research company with multi-disciplinary skills in synthetic

The sales revenue of the company increased from Rs 224.60 crore in FY 2008-09 to Rs 252 crore in FY 2009-10 clocking a growth of 24 percent. There are plans of listing in the coming fiscal.

Syngene has consolidated its position as one of the leading custom research organizations in India. The commencement of operations from its recently commissioned biologics pilot plant, coupled with formulation development and other new service offerings, positions Syngene as an ideal partner for providing high quality discovery for large and small molecules.

The company recently partnered with Endo Pharmaceuticals to develop a novel biological therapeutic molecule against cancer. Under the terms of the agreement, Endo will retain the rights of the molecule developed, and in return, Syngene will receive research fees, milestone payments and success fees from Endo. This is first-of-its-kind biological therapeutic entity.

This also marks Endo's foray into the biologics space and is in line with its strategy of building its pipeline using a virtual discovery approach in conjunction with its in-licensing

Syngene conducts high value R&D in early stage drug discovery and development for a diverse global clients. From early stage discovery and process development through to cGMP manufacturing, Syngene provides customized R&D services to pharmaceutical and biotechnology companies on a strong platform of confidentiality and intellectual

Established in 1994, Syngene was India's first custom research organization to receive special export status from the Government of India. Over the past 16 years, the company has successfully partnered with leading players in the global pharma industry across a range of challenging programs, right from discovery to supply of complex development

The company has developed skills in synthetic chemistry and molecular biology, process chemistry and cell line services. The company is also leveraging the convergence of IT

Early 2007, the company entered into a research partnership with Bristol-Myers Squibb (BMS). Through this partnership, it is providing R&D services for discovery and early

Last year, Syngene International has partnered with Sapiient Discovery, a US-based biotech company, offering fully-integrated drug discovery services.